Spinal cord injury without radiographic abnormality (SCIWORA) in adults: A report of two cases

Spinal cord injury without any radiographic abnormality (SCIWORA) is rare in adults. We describe here two case reports of adult patients, who presented to us with quadriplegia, following a road traffic accident. Plain radiography and computed tomography (CT) of cervical spine were normal. Hence the patients were diagnosed as cases of adult SCIWORA. However, subsequent magnetic resonance imaging (MRI) of the two patients revealed cervical cord injury in the form of cord contusion and disc protrusion, respectively. Patient with cord contusion was managed medically, whereas the patient with disc lesion was treated with discectomy. Patient treated with discectomy showed marked improvement. Therefore, patients having no osseous injury on X ray and CT scan should have an MRI study done to look for surgically correctable pathology. As in such rare patients of SCIOWRA an early diagnosis and timely intervention is crucial; with MRI playing a pivotal role

Evaluating the Influence of China Pakistan Economic Corridor on Pakistan's Construction Industry: Opportunities and Challenges

The China-Pakistan Economic Corridor (CPEC) is a flagship project of the Belt and Road Initiative (BRI), aimed at connecting western China to the port of Gwadar in southwest Pakistan through an extensive network of infrastructure, trade, and investment linkages. The construction of CPEC in Pakistan has significant implications for the country's construction industry, which plays a vital role in economic growth, employment, and development. This research paper employs a mixed-methods approach, including a literature review, surveys of 100 construction firms in Pakistan, and in-depth interviews with government officials, industry experts, and environmental NGOs, to examine the impact of CPEC construction on Pakistan's construction industry. The main objective of the research is to identify potential opportunities and obstacles for transnational operation management of firms within the BRI environment. The findings of this study provide valuable insights for businesses and decision-makers aiming to maximize the benefits of CPEC development while mitigating potential negative repercussions

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

Background: Tranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding. Methods: We did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124. Findings: Between July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98). Interpretation: We found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial

Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990-2019, for 204 countries and territories: the Global Burden of Diseases Study 2019

Background: The sustainable development goals (SDGs) aim to end HIV/AIDS as a public health threat by 2030. Understanding the current state of the HIV epidemic and its change over time is essential to this effort. This study assesses the current sex-specific HIV burden in 204 countries and territories and measures progress in the control of the epidemic. Methods: To estimate age-specific and sex-specific trends in 48 of 204 countries, we extended the Estimation and Projection Package Age-Sex Model to also implement the spectrum paediatric model. We used this model in cases where age and sex specific HIV-seroprevalence surveys and antenatal care-clinic sentinel surveillance data were available. For the remaining 156 of 204 locations, we developed a cohort-incidence bias adjustment to derive incidence as a function of cause-of-death data from vital registration systems. The incidence was input to a custom Spectrum model. To assess progress, we measured the percentage change in incident cases and deaths between 2010 and 2019 (threshold >75% decline), the ratio of incident cases to number of people living with HIV (incidence-to-prevalence ratio threshold <0·03), and the ratio of incident cases to deaths (incidence-to-mortality ratio threshold <1·0). Findings: In 2019, there were 36·8 million (95% uncertainty interval [UI] 35·1–38·9) people living with HIV worldwide. There were 0·84 males (95% UI 0·78–0·91) per female living with HIV in 2019, 0·99 male infections (0·91–1·10) for every female infection, and 1·02 male deaths (0·95–1·10) per female death. Global progress in incident cases and deaths between 2010 and 2019 was driven by sub-Saharan Africa (with a 28·52% decrease in incident cases, 95% UI 19·58–35·43, and a 39·66% decrease in deaths, 36·49–42·36). Elsewhere, the incidence remained stable or increased, whereas deaths generally decreased. In 2019, the global incidence-to-prevalence ratio was 0·05 (95% UI 0·05–0·06) and the global incidence-to-mortality ratio was 1·94 (1·76–2·12). No regions met suggested thresholds for progress. Interpretation: Sub-Saharan Africa had both the highest HIV burden and the greatest progress between 1990 and 2019. The number of incident cases and deaths in males and females approached parity in 2019, although there remained more females with HIV than males with HIV. Globally, the HIV epidemic is far from the UNAIDS benchmarks on progress metrics. Funding: The Bill & Melinda Gates Foundation, the National Institute of Mental Health of the US National Institutes of Health (NIH), and the National Institute on Aging of the NIH

Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019.

The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019) provided systematic estimates of incidence, morbidity, and mortality to inform local and international efforts toward reducing cancer burden. To estimate cancer burden and trends globally for 204 countries and territories and by Sociodemographic Index (SDI) quintiles from 2010 to 2019. The GBD 2019 estimation methods were used to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALYs) in 2019 and over the past decade. Estimates are also provided by quintiles of the SDI, a composite measure of educational attainment, income per capita, and total fertility rate for those younger than 25 years. Estimates include 95% uncertainty intervals (UIs). In 2019, there were an estimated 23.6 million (95% UI, 22.2-24.9 million) new cancer cases (17.2 million when excluding nonmelanoma skin cancer) and 10.0 million (95% UI, 9.36-10.6 million) cancer deaths globally, with an estimated 250 million (235-264 million) DALYs due to cancer. Since 2010, these represented a 26.3% (95% UI, 20.3%-32.3%) increase in new cases, a 20.9% (95% UI, 14.2%-27.6%) increase in deaths, and a 16.0% (95% UI, 9.3%-22.8%) increase in DALYs. Among 22 groups of diseases and injuries in the GBD 2019 study, cancer was second only to cardiovascular diseases for the number of deaths, years of life lost, and DALYs globally in 2019. Cancer burden differed across SDI quintiles. The proportion of years lived with disability that contributed to DALYs increased with SDI, ranging from 1.4% (1.1%-1.8%) in the low SDI quintile to 5.7% (4.2%-7.1%) in the high SDI quintile. While the high SDI quintile had the highest number of new cases in 2019, the middle SDI quintile had the highest number of cancer deaths and DALYs. From 2010 to 2019, the largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles. The results of this systematic analysis suggest that the global burden of cancer is substantial and growing, with burden differing by SDI. These results provide comprehensive and comparable estimates that can potentially inform efforts toward equitable cancer control around the world.Funding/Support: The Institute for Health Metrics and Evaluation received funding from the Bill & Melinda Gates Foundation and the American Lebanese Syrian Associated Charities. Dr Aljunid acknowledges the Department of Health Policy and Management of Kuwait University and the International Centre for Casemix and Clinical Coding, National University of Malaysia for the approval and support to participate in this research project. Dr Bhaskar acknowledges institutional support from the NSW Ministry of Health and NSW Health Pathology. Dr Bärnighausen was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, which is funded by the German Federal Ministry of Education and Research. Dr Braithwaite acknowledges funding from the National Institutes of Health/ National Cancer Institute. Dr Conde acknowledges financial support from the European Research Council ERC Starting Grant agreement No 848325. Dr Costa acknowledges her grant (SFRH/BHD/110001/2015), received by Portuguese national funds through Fundação para a Ciência e Tecnologia, IP under the Norma Transitória grant DL57/2016/CP1334/CT0006. Dr Ghith acknowledges support from a grant from Novo Nordisk Foundation (NNF16OC0021856). Dr Glasbey is supported by a National Institute of Health Research Doctoral Research Fellowship. Dr Vivek Kumar Gupta acknowledges funding support from National Health and Medical Research Council Australia. Dr Haque thanks Jazan University, Saudi Arabia for providing access to the Saudi Digital Library for this research study. Drs Herteliu, Pana, and Ausloos are partially supported by a grant of the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0084. Dr Hugo received support from the Higher Education Improvement Coordination of the Brazilian Ministry of Education for a sabbatical period at the Institute for Health Metrics and Evaluation, between September 2019 and August 2020. Dr Sheikh Mohammed Shariful Islam acknowledges funding by a National Heart Foundation of Australia Fellowship and National Health and Medical Research Council Emerging Leadership Fellowship. Dr Jakovljevic acknowledges support through grant OI 175014 of the Ministry of Education Science and Technological Development of the Republic of Serbia. Dr Katikireddi acknowledges funding from a NHS Research Scotland Senior Clinical Fellowship (SCAF/15/02), the Medical Research Council (MC_UU_00022/2), and the Scottish Government Chief Scientist Office (SPHSU17). Dr Md Nuruzzaman Khan acknowledges the support of Jatiya Kabi Kazi Nazrul Islam University, Bangladesh. Dr Yun Jin Kim was supported by the Research Management Centre, Xiamen University Malaysia (XMUMRF/2020-C6/ITCM/0004). Dr Koulmane Laxminarayana acknowledges institutional support from Manipal Academy of Higher Education. Dr Landires is a member of the Sistema Nacional de Investigación, which is supported by Panama’s Secretaría Nacional de Ciencia, Tecnología e Innovación. Dr Loureiro was supported by national funds through Fundação para a Ciência e Tecnologia under the Scientific Employment Stimulus–Institutional Call (CEECINST/00049/2018). Dr Molokhia is supported by the National Institute for Health Research Biomedical Research Center at Guy’s and St Thomas’ National Health Service Foundation Trust and King’s College London. Dr Moosavi appreciates NIGEB's support. Dr Pati acknowledges support from the SIAN Institute, Association for Biodiversity Conservation & Research. Dr Rakovac acknowledges a grant from the government of the Russian Federation in the context of World Health Organization Noncommunicable Diseases Office. Dr Samy was supported by a fellowship from the Egyptian Fulbright Mission Program. Dr Sheikh acknowledges support from Health Data Research UK. Drs Adithi Shetty and Unnikrishnan acknowledge support given by Kasturba Medical College, Mangalore, Manipal Academy of Higher Education. Dr Pavanchand H. Shetty acknowledges Manipal Academy of Higher Education for their research support. Dr Diego Augusto Santos Silva was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil Finance Code 001 and is supported in part by CNPq (302028/2018-8). Dr Zhu acknowledges the Cancer Prevention and Research Institute of Texas grant RP210042

Plant Mediated Green Synthesis of CuO Nanoparticles: Comparison of Toxicity of Engineered and Plant Mediated CuO Nanoparticles towards Daphnia magna

Research on green production methods for metal oxide nanoparticles (NPs) is growing, with the objective to overcome the potential hazards of these chemicals for a safer environment. In this study, facile, ecofriendly synthesis of copper oxide (CuO) nanoparticles was successfully achieved using aqueous extract of Pterospermum acerifolium leaves. P. acerifolium-fabricated CuO nanoparticles were further characterized by UV-Visible spectroscopy, field emission scanning electron microscopy (FE-SEM), energy dispersive X-ray (EDX), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectroscopy (XPS) and dynamic light scattering (DLS). Plant-mediated CuO nanoparticles were found to be oval shaped and well dispersed in suspension. XPS confirmed the elemental composition of P. acerifolium-mediated copper nanoparticles as comprised purely of copper and oxygen. DLS measurements and ion release profile showed that P. acerifolium-mediated copper nanoparticles were more stable than the engineered CuO NPs. Copper oxide nanoparticles are used in many applications; therefore, their potential toxicity cannot be ignored. A comparative study was performed to investigate the bio-toxic impacts of plant-synthesized and engineered CuO nanoparticles on water flea Daphnia. Experiments were conducted to investigate the 48-h acute toxicity of engineered CuO NPs and plant-synthesized nanoparticles. Lower EC50 value 0.102 ± 0.019 mg/L was observed for engineered CuO NPs, while 0.69 ± 0.226 mg/L was observed for plant-synthesized CuO NPs. Additionally, ion release from CuO nanoparticles and 48-h accumulation of these nano CuOs in daphnids were also calculated. Our findings thus suggest that the contribution of released ions from nanoparticles and particles/ions accumulation in Daphnia needs to be interpreted with care

Polymeric Nanocomposites of Iron–Oxide Nanoparticles (IONPs) Synthesized Using <i>Terminalia chebula</i> Leaf Extract for Enhanced Adsorption of Arsenic(V) from Water

This study demonstrates the ecofriendly synthesis of iron&#8315;oxide nanoparticles (IONPs) and their stabilization with polymers, i.e., chitosan (C) and polyvinyl alcohol (PVA)&#8315;alginate (PA), along with a further investigation for the removal of arsenic(As(V)) from water. IONPs with an average diameter of less than 100 nm were prepared via a green synthesis process using an aqueous leaf extract of Terminalia chebula. Batch experiments were conducted to compare the removal efficiency of As(V) by these adsorbents. Factors such as pH and adsorbent dosages significantly affected the removal of arsenate As(V) by IONPs and polymer-supported reactive IONPs. Several adsorption kinetic models, such as pseudo first-order, and pseudo second-order Langmuir and Freundlich isotherms, were used to describe the adsorption of As(V). The removal of As(V) by IONPs follows the Langmuir adsorption isotherm. The highest monolayer saturation adsorption capacity as obtained from the Langmuir adsorption isotherm for IONPs was 28.57 mg/g. As(V) adsorption by polymer-supported IONPs best fit the Freundlich model, and maximum adsorption capacities of 34.4 mg/g and 40.3 mg/g were achieved for chitosan- and PVA&#8315;alginate-supported IONPs, respectively. However, among these absorbents, PVA&#8315;alginate-supported IONPs were found to be more effective than the other adsorbents in terms of adsorption, stability, and reusability

Strategies and innovations for combatting diseases in animals (Review)

Emerging and re-emerging infectious diseases pose significant challenges to animal and public health, and are aligning with global food security concerns. Anthropogenic activities, such as changes in climate, agricultural procedures and farming practices contribute to the spread of zoonotic infections in new geographical areas. Overall diagnostic quality and treatment options have improved over the past few decades. The re-emergence of old and new lethal diseases, such as highly pathogenic avian influenza in animals and humans, along with recurring epidemics, is increasingly threatening different sectors, including the animal care industry and veterinary medicine. The rapid pace of the animal industry, environmental change and socioeconomic burdens are influencing and challenging veterinarians, farmers and epidemiologists in their capacity to survey and control the spread of diseases in animals, and signify the useful impacts on their livelihoods and environment. There is high research interest in engineering various types of drug-loaded cues with multiple functionalities to tackle several infectious and non-infectious diseases. Additionally, the issue can be resolved with international-level awareness efforts, the deployment of proper design and reliable reporting standards, precise test protocols, and acceptance of the utilization of latent class models to account for, interpret and justify imperfect reference tests. The present review discusses the challenges and strategies for preventing and combating infectious diseases in livestock. Furthermore, the ongoing challenges are summarized, and future considerations, concluding remarks and recommendations are also provided for progress in the animal care and medicine sectors